Evidence map›Paper›PMID 38771248›Full record

ArticleMolecular cancer research : MCR2024

miR-497 Target Gene Regulatory Network in Angiosarcoma.

Annaleigh Benton, Noah M Moriarty, Emma Terwilliger, Bozhi Liu, Ant Murphy, Hannah Maluvac, Mae Shu, Lauren E Gartenhaus, Nimod D Janson, Claire M Pfeffer and 4 more

Abstract read
In one paragraph

Article in Molecular cancer research : MCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Annaleigh BentonDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0000-0001-6322-9994
Noah M MoriartyPurdue University Institute for Cancer Research, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-6022-9769
Emma TerwilligerDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0009-0000-8381-7902
Bozhi LiuDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0009-0007-1631-3158
Ant MurphyDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0009-0002-2467-4491
Hannah MaluvacDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0009-0002-1028-5209
Mae ShuDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0000-0001-9661-2244
Lauren E GartenhausDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0009-0003-9173-7242
Nimod D JansonDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0009-0004-8795-4030
Claire M PfefferDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0000-0003-0045-2333
Sagar M UtturkarPurdue University Institute for Cancer Research, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-3453-1948
Elizabeth I ParkinsonPurdue University Institute for Cancer Research, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-3665-5522
Nadia A LanmanPurdue University Institute for Cancer Research, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-1819-7070
Jason A HannaDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana.ORCID 0000-0001-7253-7964

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Purdue Drug Discovery Training ProgramT32GM125620 · NIGMS · PURDUE UNIVERSITY · PI DYKHUIZEN, EMILY CARLA, WEI, ALEXANDER · 2019 to 2023
$891k
Department of Biological Sciences, Purdue University Ross Lynn FellowshipGraduate School, Purdue University (Purdue Graduate School) Ross FellowshipNCI NIH HHS P30 CA023168NIGMS NIH HHS T32 GM125620Purdue University Center for Cancer ResearchRalph W. and Grace M. Showalter Research Trust Fund (Showalter Foundation)
6 · The paper itself

Abstract

Angiosarcoma is a vascular sarcoma that is highly aggressive and metastatic. Because of its rarity, treatment options for patients are limited. Therefore, more research is needed to identify possible therapeutic vulnerabilities. We previously found that conditional deletion of Dicer1 drives angiosarcoma development in mice. Given the role of DICER1 in canonical miRNA biogenesis, this suggests that miRNA loss is important in angiosarcoma development. After testing miRNAs previously suggested to have a tumor-suppressive role in angiosarcoma, miRNA-497-5p (miR-497) suppressed cell viability most significantly. We also found that miR-497 overexpression led to significantly reduced cell migration and tumor formation. To understand the mechanism of miR-497 in tumor suppression, we identified clinically relevant target genes using a combination of RNA-sequencing data in an angiosarcoma cell line, expression data from patients with angiosarcoma, and target prediction algorithms. We validated miR-497 direct regulation of cyclin-D2, cyclin-dependent kinase 6, and vesicle amine transport protein 1 (VAT1). One of these genes, VAT1, is an understudied protein that has been suggested to promote cell migration and metastasis in other cancers. Indeed, we find that pharmacologic inhibition of VAT1 with the natural product neocarzilin A reduces angiosarcoma migration. Implications: This work supports the potent tumor-suppressive abilities of miR-497 in angiosarcoma, providing evidence for its potential as a therapeutic agent, and provides insight into the mechanisms of tumor suppression through analysis of the target gene regulatory network of miR-497.

Indexed as

Gene Regulatory NetworksHemangiosarcomaMicroRNAsAnimalsCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansMiceMicroRNAsMIRN497 microRNA, human

Identifiers

PMID38771248
PMCPMC11374500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.